Physician profile
Ramesh Srinivasan
NPI 1861696452
$9,193.37
in general payments reported to CMS, 2019-2025
35 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $98.78 · 2021: $1,112 · 2022: $1,467 · 2023: $2,016 · 2024: $1,764 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,950 · Education: $16.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,950.46 |
| Education | $16.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,827.43 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Medinc of Texas | $1,186.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $643.66 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $567.95 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $517.42 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $417.16 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $288.25 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $231.25 | 2022-2024 | Dupixent |
| Qol Medical, LLC | $228.45 | 2022-2025 | Sucraid |
| Ardelyx, INC. | $217.94 | 2022-2024 | Ibsrela |
| Pfizer INC. | $188.80 | 2021-2025 | |
| Madrigal Pharmaceuticals | $188.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $174.82 | 2023-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $149.27 | 2021-2024 | Linzess |
| Daiichi Sankyo INC. | $115.89 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $114.41 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $109.09 | 2023 | Zeposia |
| Genzyme Corporation | $108.84 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $103.13 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $98.73 | 2022-2023 | Clenpiq, Rebyota |
| Phathom Pharmaceuticals, INC. | $95.52 | 2024-2025 | Voquezna |
| Vivus LLC | $77.98 | 2022-2024 | Qsymia, Pancreaze |
| Cardinal Health 110 LLC | $74.00 | 2025 | |
| Aimmune Therapeutics, INC. | $73.82 | 2024-2025 | Zenpep |
| Evoke Pharma, INC. | $73.28 | 2022-2024 | Gimoti |
| Braintree Laboratories, INC. | $70.19 | 2021-2024 | Suflave, Sutab |
| Shield Therapeutics INC | $55.09 | 2024 | |
| Medtronic, INC. | $52.88 | 2024 | Gi Genius |
| Ipsen Biopharmaceuticals, INC | $47.53 | 2024-2025 | Iqirvo |
| Covidien LP | $24.43 | 2019 | |
| Romark Laboratories, Lc | $23.35 | 2019 | |
| Shire North American Group INC | $18.73 | 2019 | |
| Celltrion USA INC. | $16.17 | 2024 | Zymfentra |
| Allergan, INC. | $13.68 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Srinivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.